A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...

This article explores methods to enhance efficiency in the drug discovery and development pipeline, focusing on optimizing ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

A new study shows how an anticancer drug triggers an 'outside in' signal that gets it sucked into a cancer cell. The work reveals a new signaling mechanism that could be exploited for delivering other ...

The pre-B-cell receptor (pre-BCR), which comprises two Igμ chains and two germline-encoded surrogate light chains (SLC) that are associated with the signalling subunits Igα and Igβ, is formed ...

GLP-1 receptor agonists stimulate the body to release insulin after eating. They also decrease glucagon release—preventing the body from mobilizing extra sugars—and slow stomach emptying.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.